Applicable from 5 March 2012 Osteoporosis: Bisphosphonates*, denosumab, raloxifene and strontium ranelate * Conditional reimbursement for alendronate is available for patients with low-energy hip fractures. Consequently, single reimbursement for alendronate should only be applied for on behalf of patients suffering from other disorders, cf. below. Guiding criteria for single reimbursement For other medicines than alendronate it must appear from the application why the patient cannot use alendronate. Single reimbursement is then usually granted when at least one of the criteria below are satisfied. • The application concerns a patient having suffered a low-impact hip or vertebral fracture (i.e. a fracture caused by daily activities or a fall of the same impact) which has been diagnosed by X-ray. A copy of the X-ray report must be enclosed with the application. A vertebral fracture is defined as: 1. A > 20% reduction of anterior vertebral height compared to posterior vertebral height. 2. A > 20% reduction of anterior, middle or posterior vertebral height compared to normal vertebrae above or below. • The application concerns a person with at least one risk factor (see table below) for development of osteoporosis and where a BMD measurement of the spine and/or hip has shown a T-score < -2.5. The patient’s risk factors must appear from the application. • The application concerns a person with a T-score < -4 without the presence of other risk factors. • The application concerns a person in current or planned systematic glucocorticoid treatment (corresponding to prednisolone > 5 mg/day for more than 3 months or intermittent glucocorticoid treatment with a total duration of more than 3 months within one year) and where a BMD measurement of the spine and/or hip has shown a T-score < -1. If the patient’s risk factors do not appear from the application, it will be returned for submission of the missing information. Table. Risk factors for development of osteoporotic fracture Hereditary predisposition in direct line of ascent Women with low body weight (BMI < 19kg/m2) Previous low-impact fracture Osteogenesis imperfecta Abnormally early menopause (< 45 years) Systemic glucocorticoid therapy Smoking Excessive alcohol consumption Elderly with an increased risk of fracture due to increased risk of falls Treatment with aromatase inhibitors Treatment with antiandrogens for prostate cancer Age > 80 years Osteoporosis-related diseases Osteoporosis-related diseases include for example: Anorexia nervosa Malabsorption (including previous gastrectomi) Primary hyperparathyroidism Hyperthyroidism Organ transplantation Chronic renal insufficiency Prolonged immobilisation Cushing's syndrome Bechterew’s disease Mastocytosis Rheumatoid arthritis Myelomatosis Severe COPD .